Skip to content
Lesson 4 of 5·10 min·+40 impact

The Lobbying Math

Key Concepts

Regulatory Capture(George Stigler)
When a regulatory agency — created to act in the public interest — instead advances the interests of the industry it's supposed to regulate, because the industry has more resources, expertise, and sustained attention than the public.
Revolving Door(Public Citizen)
The movement of personnel between government regulatory roles and the industries they regulate. In pharma, FDA officials frequently leave for high-paying industry positions, and industry executives take government roles overseeing their former employers.

# The Lobbying Math

Hook: The pharmaceutical industry spends more on lobbying than any other industry in America. In 2022 alone: $374 million. That's over $1 million per day, or roughly $700,000 per member of Congress.

The Numbers

According to OpenSecrets, the pharmaceutical and health products industry has been the top lobbying spender in the United States for over two decades:

  • **2022:** $374 million
  • **2021:** $357 million
  • **2020:** $309 million
  • **Total since 1998:** Over $7.5 billion

For context, the oil and gas industry — often cited as the most powerful lobby in Washington — spent $124 million in 2022. Pharma outspent them 3 to 1.

The industry also employs more than 1,800 registered lobbyists — roughly 3.4 lobbyists for every member of Congress.

How to Read OpenSecrets

OpenSecrets (opensecrets.org) is a nonpartisan research organization that tracks money in politics. Here's how to use it:

Look up your representative: Go to opensecrets.org → Members of Congress → search by name or state. You'll see their top donors, industry breakdown, and committee assignments.

Check the industry page: Go to opensecrets.org → Industries → Pharmaceuticals/Health Products. You'll see total spending by cycle, top recipients, and the split between parties.

Read the revolving door data: OpenSecrets tracks the movement of former government officials into lobbying roles and vice versa. The pharmaceutical industry has one of the highest revolving-door rates.

The Return on Investment

Let's do the math on the non-interference clause:

  • **Lobbying investment** (estimated portion allocated to preserving the clause over 19 years): ~$2–3 billion
  • **Additional revenue from non-negotiated prices** (estimated, based on VA pricing comparisons): $500+ billion over the same period
  • **Return on lobbying investment:** Roughly 150x to 250x

This is not hyperbole. The CBO estimated that the Inflation Reduction Act's drug pricing provisions would reduce the federal deficit by $237 billion over 10 years. That $237 billion was, effectively, the amount the industry had been overcharging Medicare — and protecting through lobbying.

The Key Insight

Lobbying is an investment with a measurable return. The pharmaceutical industry doesn't spend $374 million per year out of civic virtue. It spends that money because the return — in favorable regulation, delayed reform, and preserved pricing power — vastly exceeds the cost. Understanding lobbying as an economic transaction, not a political abstraction, changes how you evaluate every policy debate.

Ready to act?

Now that you understand the background, take direct action.

Take action →